% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{GonzalezMaldonado:167442,
      author       = {S. Gonzalez Maldonado$^*$ and T. Johnson$^*$ and E.
                      Motsch$^*$ and S. Delorme$^*$ and R. Kaaks$^*$},
      title        = {{C}an autoantibody tests enhance lung cancer screening?-an
                      evaluation of {E}arly{CDT}®-{L}ung in context of the
                      {G}erman {L}ung {C}ancer {S}creening {I}ntervention {T}rial
                      ({LUSI}).},
      journal      = {Translational Lung Cancer Research},
      volume       = {10},
      number       = {1},
      issn         = {2226-4477},
      address      = {[S.l.]},
      reportid     = {DKFZ-2021-00346},
      pages        = {233 - 242},
      year         = {2021},
      note         = {#EA:C020#LA:C020#},
      abstract     = {Tumor-associated autoantibodies are considered promising
                      markers for early lung cancer detection; so far, however,
                      their capacity to detect cancer has been tested mostly in a
                      clinical context, but not in population screening settings.
                      This study evaluates the early detection accuracy, in terms
                      of sensitivity and specificity, of EarlyCDT®-Lung-a test
                      panel of seven tumor-associated autoantibodies optimized for
                      lung cancer detection-using blood samples originally
                      collected as part of the German Lung Cancer Screening
                      Intervention Trial.The EarlyCDT®-Lung test was performed
                      for all participants with lung cancer detected via low-dose
                      computed tomography and with available blood samples taken
                      at detection, and for 180 retrospectively selected
                      cancer-free participants at the end of follow-up: 90
                      randomly selected from among all cancer-free participants
                      (baseline controls) and 90 randomly selected from among
                      cancer-free participants with suspicious imaging findings
                      (suspicious nodules controls). Sensitivity and specificity
                      of lung cancer detection were estimated in the case group
                      and the two control groups, respectively.In the case group,
                      the test panel showed a sensitivity of only $13.0\%$ $(95\%$
                      CI: $4.9-26.3\%).$ Specificity was estimated at $88.9\%$
                      $(95\%$ CI: $80.5-94.5\%)$ in the baseline control group,
                      and $91.1\%$ $(95\%$ CI: $83.2-96.1\%)$ among controls
                      presenting CT-detected nodules.The test panel showed
                      insufficient sensitivity for detecting lung cancer at an
                      equally early stage as with low-dose computed tomography
                      screening.},
      keywords     = {Lung cancer screening (Other) / autoantibody test (Other) /
                      early detection (Other)},
      cin          = {C020 / E010},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331 / I:(DE-He78)E010-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33569307},
      pmc          = {pmc:PMC7867751},
      doi          = {10.21037/tlcr-20-727},
      url          = {https://inrepo02.dkfz.de/record/167442},
}